<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fludarabine combination chemotherapy achieves high response rates in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the incidence and characteristics of treatment-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) after treatment with fludarabine in combination for <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and identify risk factors for its development </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 176 patients treated with fludarabine combination were followed for a median of 41 months (range 6-125 months) </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 19 cases of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> have been identified for an overall rate of 10.8% </plain></SENT>
<SENT sid="4" pm="."><plain>Median overall survival post-t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> diagnosis was 11 months </plain></SENT>
<SENT sid="5" pm="."><plain>Patients developing t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> included 11/54 with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) (crude rate 20.4%), 5/82 with CLL (6.1%) and 3/24 with <z:hpo ids='HP_0005508'>Waldenstrom macroglobulinemia</z:hpo> or marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (12.5%) </plain></SENT>
<SENT sid="6" pm="."><plain>Most patients had other cytotoxic treatments (median 4, range 0-7) but three with FL had fludarabine combination as their only line of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Of the eleven patients (6.3%) who received <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> with their first fludarabine combination, four (36.4%) developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.007) </plain></SENT>
<SENT sid="8" pm="."><plain>There was a trend toward prior cytotoxic therapy increasing the risk for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.067) </plain></SENT>
<SENT sid="9" pm="."><plain>Fludarabine combination chemotherapy is associated with a moderate risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> particularly when combined with <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>This complication should be considered when evaluating the potential benefit of this treatment in <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
</text></document>